Education
About Us
Working with TipRanks
Follow Us
Immucell (ICCC)
:ICCC
ICCC Stock Chart & Stats
$6.16
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.16
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$3.38 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)18.70K
Market Cap
$55.00M
Enterprise Value$71.12M
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$14.27M
Price to Earnings (P/E)32.3
Beta-0.27
Next Earnings
Nov 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding9,045,851
10 Day Avg. Volume17,725
30 Day Avg. Volume18,699
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda13.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immucell News
ICCC FAQ
What was Immucell’s price range in the past 12 months?
Immucell lowest stock price was $3.38 and its highest was $7.60 in the past 12 months.
What is Immucell’s market cap?
Immucell’s market cap is $55.00M.
When is Immucell’s upcoming earnings report date?
Immucell’s upcoming earnings report date is Nov 17, 2025 which is in 21 days.
How were Immucell’s earnings last quarter?
Immucell released its earnings results on Aug 14, 2025. The company reported $0.056 earnings per share for the quarter, beating the consensus estimate of N/A by $0.056.
Is Immucell overvalued?
According to Wall Street analysts Immucell’s price is currently Overvalued.
Does Immucell pay dividends?
Immucell does not currently pay dividends.
What is Immucell’s EPS estimate?
Immucell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell have?
Immucell has 9,045,851 shares outstanding.
What happened to Immucell’s price movement after its last earnings report?
Immucell reported an EPS of $0.056 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.226%.
Which hedge fund is a major shareholder of Immucell?
Currently, no hedge funds are holding shares in ICCC
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.83%
12-Months-Change
Fundamentals
Return on Equity
6.61%
Trailing 12-Months
Asset Growth
11.62%
Trailing 12-Months
Company Description
Immucell
Immucell Corporation (ICCC) is a publicly traded biotechnology company focused on developing and commercializing innovative products for the veterinary health market. The company primarily operates in the animal health sector and specializes in creating products that enhance the health and productivity of livestock, particularly dairy and beef cattle. Immucell's core product offerings include its flagship product, First Defense, which is designed to prevent disease in newborn calves by providing them with essential immunoglobulins.
ICCC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
ImmuCell showed strong financial performance with significant sales growth and gross margin improvement, alongside a successful debt refinancing. However, challenges remain with potential sales softening, FDA approval delays for Re-Tain, and the need to regain customer trust after supply issues.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
0.05% Insiders
4.51% Mutual Funds
3.62% Other Institutional Investors
88.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---